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Amiodarone, a class III anti-arrhythmic drug, has been used in equine and human 
medicine to treat atrial fibrillation (AF). The aim of this retrospective study was to 
report the effect of amiodarone administered IV during transvenous electrical 
cardioversion (TVEC) in case of failure to restore sinus rhythm (SR) or immediate 
recurrence of AF (IRAF). Data from 11 Warmblood horses with AF receiving 
amiodarone (5mg/kg over 30 minutes) during the TVEC procedure were reviewed. 
Mean age was 9.5 years. AF duration varied from two weeks to 1.5 year. Mild, 
moderate or severe mitral (n=8), tricuspid (n=10) and aortic (n=4) valvular 
regurgitations were present. Five horses had left atrial dilatation. TVEC was 
performed using ‘Guelph’ catheters (n=5) or ‘Gaeltec’ catheters (n=6). When TVEC, 
using energy levels of 150 to 360J with 50J increments, failed to restore SR (n=7), 
amiodarone was administered. SR could be restored (Fig.1) in 4 horses where initial 
TVEC failed, with a median of 1 (range 1-6) shock at 360J. In IRAF cases (n=4), 
amiodarone was administered after a median number of 3.5 (range 3-4) relapses 
within a median of 9 (range 0.05-30) minutes after initial cardioversion. All IRAF 
cases were discharged in SR. No side effects were noted except for a transient 
decrease in blood pressure during amiodarone infusion (n=8). These results suggest 
that the combined use of IV amiodarone with TVEC can increase success rates in 
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